Challenges and Opportunities of Read-Across for the Tumor Promotion Effects of Microcystins

Pestana, CB ORCID: 0000-0002-0468-8303, Leme, DM, Moreira Silva, EZ, Kiessig, S, Firman, JW ORCID: 0000-0003-0319-1407, Kneuer, C, Marx-Stoelting, P and Cronin, MTD ORCID: 0000-0002-6207-4158 (2025) Challenges and Opportunities of Read-Across for the Tumor Promotion Effects of Microcystins. Regulatory Toxicology and Pharmacology. ISSN 0273-2300

Preview

Text Challenges and Opportunities of Read-Across for the Tumor Promotion Effects of Microcystins.pdf - Accepted Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

The microcystins (MCs) are a family of cyclic oligopeptides toxins expressed in at least 30 cyanobacterial species and are liable to pose significant hazard to human health due to hepatotoxicity. Microcystin-leucine arginine (MC-LR) is the most extensively studied and toxic congener and classified as possibly carcinogenic to humans based on tumor promotion activity in the liver. Given the substantial toxicity data gaps for the MCs, read-across was assessed to evaluate the tumor promotion effects of a series of data-poor MC congeners based on in vivo information for MC-LR as the source molecule. Lines of evidence from in silico estimates of structural similarity, physico-chemical properties, hepatotoxicity, genotoxic and carcinogenicity were compiled to support the filling of data gaps. Uncertainties were evaluated according to scenario 4 of the European Chemicals Agency’s (ECHA’s) Read-Across Assessment Framework (RAAF). The read-across process followed a harmonized framework previously proposed to apply the common principles together with new approach methodology (NAM) information. Lines of evidence showed consistency across the MC congeners and the uncertainties were found to be acceptable for data gap filling. Read-across strategies, with known caveats and restrictions, were shown to be applicable for large, complex molecules such as the MCs.

Item Type:	Article
Uncontrolled Keywords:	1115 Pharmacology and Pharmaceutical Sciences; Toxicology; 3214 Pharmacology and pharmaceutical sciences
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Elsevier
Date of acceptance:	5 September 2025
Date of first compliant Open Access:	12 September 2025
Date Deposited:	12 Sep 2025 10:09
Last Modified:	12 Sep 2025 10:15
DOI or ID number:	10.1016/j.yrtph.2025.105938
URI:	https://researchonline.ljmu.ac.uk/id/eprint/27152

View Item